MetaCap

Orchestra BioMed (OBIO) vs Philip Morris International (PM)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Orchestra BioMed (OBIO) has outperformed Philip Morris International (PM) over the past year, gaining 45.3% versus a gain of 18.6%. Over five years, PM leads with a +107.6% price change compared with -33.3% for OBIO. Philip Morris International is the larger company by market cap ($286.93 billion vs $517.9 million), about 554.1 times the size, while Orchestra BioMed is growing revenue faster (+1169.2% vs +7.3%).

Philip Morris International pays a dividend yielding 3.26%, while Orchestra BioMed does not currently pay one. Philip Morris International converts more of its revenue into profit, with a net margin of 27.9% versus -157.4%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

OBIO+45.25%PM+18.58%
+69%+21%-27%
Nov 21, 20251 yearNov 20, 2026
OBIO-33.27%PM+103.64%
+141%+28%-86%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

OBIO versus PM key metrics
MetricOBIOPM
Share price$6.58$184.09
Market cap$517.88M$286.93B
1-day change-6.00%-1.26%
YTD return+58.55%+14.77%
1-year return+45.25%+18.58%
5-year return-33.27%+107.59%
P/E ratio (TTM)—26.87
Forward P/E—20.36
EPS (TTM)$-0.75$6.85
Dividend yield0.00%3.26%
Annual dividend$0.00$6.01
Revenue (latest FY)$33.48M$40.65B
Revenue growth (YoY)+1169.22%+7.31%
Net income (latest FY)$-52.70M$11.35B
Gross margin99.43%67.12%
Operating margin-154.73%36.64%
Net margin-157.40%27.92%
52-week high$7.83$214.35
52-week low$3.46$146.35
Distance from 52-week high-15.91%-14.12%
Analyst consensusstrong_buybuy
Avg. price target upside+101.98%+15.54%
Average volume420.19K4.76M
Shares outstanding78.70M1.56B
Employees8684,900
SectorHealth CareHealth Care
Industry Medicinal Chemicals and Botanical Products Medicinal Chemicals and Botanical Products

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Philip Morris International is about 554.1 times larger than Orchestra BioMed by market value ($286.93B vs $517.88M).
  • OBIO has outperformed PM by 26.7 percentage points over the past year.
  • Philip Morris International offers a meaningfully higher dividend yield (3.26% vs 0.00%).
  • Philip Morris International is more profitable, keeping 27.9 cents of every revenue dollar as net income versus -157.4 cents for Orchestra BioMed.
  • Orchestra BioMed grew revenue faster in its latest fiscal year (+1169.22% vs +7.31%).

About Orchestra BioMed

OBIO stock →

Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States.

Health Care · Medicinal Chemicals and Botanical Products · 86 employees

About Philip Morris International

PM stock →

Philip Morris International Inc. operates as a tobacco company.

Health Care · Medicinal Chemicals and Botanical Products · 84,900 employees

OBIO vs PM FAQ

Which is bigger, Orchestra BioMed or Philip Morris International?

Philip Morris International (PM) is larger, with a market capitalization of $286.93B compared with $517.88M for Orchestra BioMed (OBIO).

Which stock has performed better over the past year, OBIO or PM?

OBIO returned +45.25% over the past 12 months, compared with +18.58% for PM (price return, excluding dividends). Past performance does not predict future results.

Which pays a higher dividend, Orchestra BioMed or Philip Morris International?

Philip Morris International pays a dividend yielding 3.26%, while Orchestra BioMed does not currently pay a regular dividend.

Are Orchestra BioMed and Philip Morris International in the same industry?

Yes. Both are classified in the Medicinal Chemicals and Botanical Products industry within the Health Care sector.

More comparisons